Manneh, R.; Lema, M.; Carril-Ajuria, L.; Ibatá, L.; MartÃnez, S.; Castellano, D.; de Velasco, G.
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Biomedicines 2022, 10, 577.
https://doi.org/10.3390/biomedicines10030577
AMA Style
Manneh R, Lema M, Carril-Ajuria L, Ibatá L, MartÃnez S, Castellano D, de Velasco G.
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Biomedicines. 2022; 10(3):577.
https://doi.org/10.3390/biomedicines10030577
Chicago/Turabian Style
Manneh, Ray, Mauricio Lema, LucÃa Carril-Ajuria, Linda Ibatá, Susan MartÃnez, Daniel Castellano, and Guillermo de Velasco.
2022. "Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials" Biomedicines 10, no. 3: 577.
https://doi.org/10.3390/biomedicines10030577
APA Style
Manneh, R., Lema, M., Carril-Ajuria, L., Ibatá, L., MartÃnez, S., Castellano, D., & de Velasco, G.
(2022). Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Biomedicines, 10(3), 577.
https://doi.org/10.3390/biomedicines10030577